Video

Few College Students Have Received the H1N1 Vaccine

Night Lights Could Lead to Depression

Cervarix Has Been Approved by the FDA

The FDA Is Studying the Effects of Lasik Surgery

Painkillers Can Dull the Effects of Childhood Vaccines

Childbirth May Becoming More Complicated

Botox Sponges Might Help Nose Allergies

The FDA Advises on How to Properly Dispose of Medicine

A French Study Shows Cell Phones Do Not Affect Humans

MRIs May Lead to More Back Surgery

Your More Likely to Wash Your Hands If Someone's Watching

Co-Sleeping Is a Leading Cause of SIDS

Night Shifts Don't Have a Major Effect On Surgeons

Exercise May Counter Fatigue from Chemotherapy

Healthy Neighborhoods Could Lower the Risk for Diabetes

Drug Could Help Treat Small HER2-Positive Breast Tumors

Posted on 11/03/2009, 12:00
By -- Randy Dotinga

Researcher urges studies to determine benefits of anti-HER2 therapies

TUESDAY, Nov. 3 (HealthDay News) -- Women with a relatively uncommon type of breast cancer are significantly more likely to face its recurrence and spread, but researchers now say these women may benefit from treatment with the breast cancer drug Herceptin.

Two studies, from the United States and Italy, examined cases of women with small (1 centimeter or less in diameter) HER2-positive breast cancers that hadn't spread to the lymph nodes. The researchers found that the cancer is more than two times more likely to recur in HER2-positive women than in women with HER2-negative breast cancers.

The U.S. study, which looked at 965 women diagnosed between 1990 and 2002, also found that HER2-positive women had a more than fivefold higher risk of metastasis, in which the cancer spreads to other parts of the body, once the cancer returns than those with HER2-negative tumors.

The researchers estimate that only one in four breast cancers are HER2-positive. The new research, published in the Nov. 2 online edition of the Journal of Clinical Oncology, looked at those with small tumors.

Currently, the guidelines don't suggest that women with such small tumors receive treatment with the drug trastuzumab (Herceptin). However, the authors of the new studies recommend that the drug be considered for them.

"We expected the risk of recurrence and metastasis in HER2-positive node-negative patients with small tumors to be higher than in women with HER2-negative tumors, but we didn't expect the magnitude of this [increased] risk to be so high," Dr. Ana M. Gonzalez-Angulo, an associate professor in the department of breast medical oncology at the University of Texas M.D. Anderson Cancer Center and lead author of the U.S. study, said in a news release from the journal's publisher. "This elevated risk is unacceptable, and indicates that women with small HER2-positive node-negative breast tumors should be offered participation in clinical trials assessing anti-HER2 therapies, such as trastuzumab [Herceptin], or other adjuvant treatment."

More information

Learn more about breast cancer from the U.S. National Cancer Institute.

SOURCE: American Society of Clinical Oncology, news release, Nov. 2, 2009

More news in Breast Cancer...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 2.7 / 5 (11 votes)